$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Difference Between Aceminib and Orebatinib: Which Is Better for You?
2026-02-01 22:25:32
Check Details
Which is better, ritexitinib or baricitinib? Comparison of effects and analysis of applicable groups
2026-02-01 22:25:32
Check Details
What is the main function of sparsentan/sparsentan? Analysis of indications and mechanism of action
2026-02-01 22:25:32
Check Details
How many years can treatment with Ixazomib/Enleri be maintained? How safe is long-term use of the medication?
2026-02-01 22:25:32
Check Details
Rubicatin/rubitin combined with irinotecan: efficacy and safety of dual-drug therapy
2026-02-01 22:25:32
Check Details
How much does it cost for one month to treat pulmonary fibrosis with pirfenidone/asrex?
2026-02-01 22:25:32
Check Details
How effective is canafenib in treating colon cancer? Clinical research and efficacy analysis
2026-02-01 22:25:32
Check Details
Which generation of targeted drugs does sotorasib belong to? Pharmacological mechanisms and therapeutic strategies
2026-02-01 22:25:32
Check Details
Targeted drug sotorasiib vs adagrasiib: Which one is more suitable for patients?
2026-02-01 22:25:32
Check Details
Afatinib price trends in 2025: will it be cheaper in the future?
2026-02-01 22:25:32
Check Details
Introduction and marketing status of dutasteride soft capsules
2026-02-01 22:25:32
Check Details
Interpretation of Elivadoven gene therapy news, therapy principles and application prospects
2026-02-01 22:25:32
Check Details
1
2
...
1398
1399
1400
1401
1402
1403
1404
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
2
Revumenib: Key Considerations Before and During Treatment
3
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
4
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
5
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
6
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
7
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
8
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits
9
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
10
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
11
Eltrombopag: TPO-Receptor Agonist in ITP and Severe Aplastic Anemia
12
Ganaxolone for CDKL5-Related Seizures: GABA-A Modulation, Not a Cure